U.S. Capital Wealth Advisors’s Inhibikase Therapeutics IKT Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$16.8K	Buy	+10,000	New	+$17.8K	﹤0.01%	1002

Other funds holding IKT

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

U.S. Capital Wealth Advisors's IKT Position: Q1 2026 in Review

U.S. Capital Wealth Advisors opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 10,000 shares worth $16.8K. The stake represents ﹤0.01% of the portfolio and ranks #1002 among its holdings.

104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

U.S. Capital Wealth Advisors held 10,000 shares of Inhibikase Therapeutics worth $16.8K as of Q1 2026.
Inhibikase Therapeutics was a new U.S. Capital Wealth Advisors position in Q1 2026.
Inhibikase Therapeutics made up ﹤0.01% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #1002 holding.
104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.